Brief: SynAct Pharma Q3 Adjusted EPS SEK -1
24/10/2023 06:32
Oct 24 (Reuters) - SynAct Pharma Q3 adjusted EPS SEK -1. * Q3 net income SEK -31.878 million * Q3 sales SEK 0 * Q3 cash flow from operating activities SEK -14.653 million * Q3 operating expenses SEK 31.692 million
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026